57 Drug Discovery & Pharmaceuticals New Analyser Exceeds Classic Zeta Potential Measurement


Microtrac introduces the new STABINO ZETA, an analyser which provides fast, precise, and reproducible zeta potential measurements due to its high resolution and data point density. The STABINO ZETA measures the zeta potential of particles in a range of 0.3 nm to 300 µm, with a concentration range of up to 40% by volume. Due to the optimised measuring technology, 5 parameters can be determined simultaneously within a few seconds: zeta potential, streaming potential, conductivity, pH value, and temperature.


When used in combination with Microtrac’s unique NANOTRAC FLEX nanoparticle analyser, particle size can be measured simultaneously in the same sample


The STABINO ZETA has many advantages over classical zeta potential measurement, not least, the capability to perform very fast titrations. The built-in titration function allows for simultaneous determination of all parameters at every titration dosage step. Possibilities include the determination of the isoelectric point which can be identified within a few minutes.


More information online: ilmt.co/PL/Bp0r 57374pr@reply-direct.com Tracking Down Pyrogens: Unique ES Buffer Enables Specifi c Detection of Endotoxin with all Common LAL Reagents


Before market release, pharmaceutical products and process materials in the laboratory and clinic, must be free of bacterial endotoxins to ensure the safety for human use. Special limit value tests (BET/ LAL) are used to preclude contamination during manufacture. In order to eliminate interferences, FUJIFILM Wako Chemicals Europe GmbH provides a unique endotoxin-specific (ES) buffer for untreated LAL reagents and formulated for all common detection methods. While all LAL reagents manufactured by Fujifilm Wako are already endotoxin specific, the buffer can make commercial reagents endotoxin specific as an additive without changing to other test systems.


The Atlantic horseshoe crab (Limulus polyphemus) has a very special immune system. If its blue blood comes into contact with endotoxin, as an immune response it forms a clot around the pathogen which prevents further infection of the wounded area. The buffer contains this special blood factor. If endotoxin is present, only its activity is permitted, causing a coagulation reaction. When the proclotting enzyme is activated, it is converted to its active form, which splits the coagulogen into an insoluble clot gel, thereby increasing the turbidity of the solution. This action makes it possible to observe qualitative or quantitative effects, proving the presence of endotoxin as well as the amount of it present. Each pre-prepared ES buffer vial contains solution for the reconstitution of 6 mL of reagent. FUJIFILM Wako offers the buffer exclusively as a separate solution for adding to untreated LAL reagents. They can simply be used with endotoxin-free water without the need for further additives or a buffer for the BET tests.


More information online: ilmt.co/PL/MBBa 57466pr@reply-direct.com


Choosing a Specialised Detector for Nitrosamine Analysis in Pharmaceutical Drugs


Over the past few years the news has seen many high-profile product recalls of various


pharmaceutical drugs that have been


found to contain nitrosamines.


Nitrosamine are carcinogenic compounds so need to be monitored to ensure unsafe levels are not found in consumer products. Governments around the world are now requiring reporting on Nitrosamine Levels. With manufacturers often finding the analysis anything but simple, with common issues including achieving the required detection limits and false positives.


The Ellutia 800 Series TEA is the ideal detector for nitrosamine analysis thanks to is selectivity and sensitivity for Nitroso compounds. For testing of pharmaceutical drugs, The 800 Series TEA can be interfaced to a chemical stripping system that allows for rapid testing of ATNC (Apparent Total N-nitrosamine content). This quickly gives an accurate result for the total nitrosamine content of a sample showing both volatile and non-volatile components.


Any positive sample can then be further analysed by an 800 Series TEA interfaced to a GC where volatile nitrosamines such as NDMA (N-Nitrosodimethylamine) can be separated and quantified.


More information online: ilmt.co/PL/P9B0 55909pr@reply-direct.com


Seal with Integrity & Reliability a


From sample evaporation, incubation to long-term storage, effortlessly protect your samples with the Ultraseal™ range of heat sealers and seals.


t


• Hands-free, tight sealing in seconds • Automated and semi-automated models • Compatible with microplates and tubes • Wide range of sealing films and foils


Designed for reliability and security. Contact:


EU/RoW: hello@porvairciences.com USA: info@jgfinneran.com


New Platform Supports Integrated Drug Discovery Solutions


A comprehensive platform designed to support every stage of cancer drug discovery projects, comprising target research, hit identification, hit-to-lead, and lead optimisation - The Reaction Oncology Platform - has been announced by a leading small molecule provider, Reaction Biology.


The Reaction Oncology Platform is based on a network of strategic partners, including oncology and biophysics by the US and Germany-based Reaction Biology, medicinal chemistry, and ADME-tox by Netherlands-based Symeres, and advanced cardiac safety/ion channel drug discovery by US/China-based PharmaCore Labs.


“Communication and problem-solving are our strengths enabling us to tackle challenging projects with close collaboration with the client and among the various teams,” said Kelvin Lam, the company’s Vice President of Strategic Business Development. “True to our reputation as a service- oriented company, we facilitate direct contact between the client and our team of multidisciplinary scientists.”


Haiching Ma, Reaction Biology’s CSO, stated: “The value of the Reaction Oncology Platform lies in the expertise of our partner network. No company can be the best in all disciplines; therefore, we choose the best partners to create a premier platform for oncology drug discovery. Our joint capabilities enable clients to create new chemical entities against challenging targets to fight cancer.”


More information online: ilmt.co/PL/JBl3 57226pr@reply-direct.com


e


S


f


i


g


c


,


a


r


e


n


l


e


h


t


e


s


e


o


t


e


s


h


n


U


l


t l


o


r


f


a


s


d


e


n


a


a


l


™


s


r


a


l


o


e


f


a


s


m


i


s


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44  |  Page 45  |  Page 46  |  Page 47  |  Page 48  |  Page 49  |  Page 50  |  Page 51  |  Page 52  |  Page 53  |  Page 54  |  Page 55  |  Page 56  |  Page 57  |  Page 58  |  Page 59  |  Page 60  |  Page 61  |  Page 62  |  Page 63  |  Page 64  |  Page 65  |  Page 66  |  Page 67  |  Page 68